Posted On: 12/23/2014 4:03:48 PM
Post# of 30066
Re: SouthBreeze #13758
Right. The second one was filed last week. Should hear back end of Feb. or early March. And then there is ESS which makes 3.
Dec. 19, 2014 - Amarantus BioScience Holdings, Inc. (AMBS), a biotechnology company focused on the development of diagnostics in Alzheimer's disease and therapeutic products in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, announced that it has applied to the U.S. Food & Drug Administration (FDA) for Orphan Drug Designation for its investigational drug MANF (mesencephalic-astrocyte-derived neurotrophic factor) as a treatment for retinal artery occlusion (RAO). RAO is a blockage of the blood supply to the retina which causes severe and sudden loss of vision.
http://finance.yahoo.com/news/amarantus-submi...00534.html
ESS granted Orphan Drug designation and Amarantus expects to commence 10 patient Phase 1/ Early Phase 2 Clinical Study in 2Q 2015
http://ir.amarantus.com/all-sec-filings/conte...load=false
Dec. 19, 2014 - Amarantus BioScience Holdings, Inc. (AMBS), a biotechnology company focused on the development of diagnostics in Alzheimer's disease and therapeutic products in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, announced that it has applied to the U.S. Food & Drug Administration (FDA) for Orphan Drug Designation for its investigational drug MANF (mesencephalic-astrocyte-derived neurotrophic factor) as a treatment for retinal artery occlusion (RAO). RAO is a blockage of the blood supply to the retina which causes severe and sudden loss of vision.
http://finance.yahoo.com/news/amarantus-submi...00534.html
ESS granted Orphan Drug designation and Amarantus expects to commence 10 patient Phase 1/ Early Phase 2 Clinical Study in 2Q 2015
http://ir.amarantus.com/all-sec-filings/conte...load=false
(0)
(0)
